Advertisement

Topics

VM BioPharma Announces First Patient Dosed In Phase III Study Of Gene Therapy Candidate VM202 For Non-Healing Diabetic Foot Ulcers

20:00 EDT 2 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: VM BioPharma Announces First Patient Dosed In Phase III Study Of Gene Therapy Candidate VM202 For Non-Healing Diabetic Foot Ulcers

NEXT ARTICLE

More From BioPortfolio on "VM BioPharma Announces First Patient Dosed In Phase III Study Of Gene Therapy Candidate VM202 For Non-Healing Diabetic Foot Ulcers"

Quick Search
Advertisement